Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov;19(6):1441-1447.
doi: 10.1177/19322968241288923. Epub 2024 Oct 12.

The Benefits of Using Continuous Glucose Monitoring to Diagnose Type 1 Diabetes

Alessandra T Ayers  1 , Cindy N Ho  1 , Jenise C Wong  2 , David Kerr  3 , Julia K Mader  4 , David C Klonoff  5
Affiliations
Editorial

The Benefits of Using Continuous Glucose Monitoring to Diagnose Type 1 Diabetes

Alessandra T Ayers et al. J Diabetes Sci Technol. 2025 Nov.
No abstract available

Keywords: CGM; T1D; islet autoantibody; stage 2 T1D; teplizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.T.A. is a consultant for Liom.C.N.H. is a consultant for Liom.J.C.W. has nothing to disclose.D.K. has received research funding from Abbott Diabetes Care.J.K.M. is a member in the advisory boards of Abbott Diabetes Care, Becton-Dickinson/Embecta, Biomea, Eli Lilly, Medtronic, Novo Nordisk, Pharmasens, Roche Diabetes Care, Sanofi and Viatris, received speaker honoraria from Abbott Diabetes Care, A. Menarini Diagnostics, Becton-Dickinson/Embecta, Boehringer-Ingelheim, Eli Lilly, MedTrust, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier and Ypsomed and is shareholder of decide Clinical Software GmbH and elyte Diagnostics.DC.K. is a consultant for Afon, Atropos Health, embecta, Glucotrack, Lifecare, Novo, Samsung, Synchneuro, and Thirdwayv.

Figures

Figure 1.
Figure 1.
PRISMA diagram summarizing the search process to identify studies that use CGM metrics to predict the development of symptomatic T1D. Adapted from Page et al under the CC-By 4.0 license (https://creativecommons.org/licenses/by/4.0/). Abbreviations: S2, stage 2; T1D, type 1 diabetes; T2D, type 2 diabetes.
See this image and copyright information in PMC

References

    1. Gong B, Yang W, Xing Y, Lai Y, Shan Z. Global, regional, and national burden of type 1 diabetes in adolescents and young adults [published online ahead of print March 5, 2024]. Pediatr Res. doi: 10.1038/s41390-024-03107-5. - DOI - PMC - PubMed
    1. Joish VN, Zhou FL, Preblick R, et al. Estimation of annual health care costs for adults with type 1 diabetes in the United States. J Manag Care Spec Pharm. 2020;26(3):311-318. doi: 10.18553/jmcp.2020.26.3.311. - DOI - PMC - PubMed
    1. Wersäll JH, Adolfsson P, Forsander G, Ricksten S, Hanas R. Delayed referral is common even when new-onset diabetes is suspected in children. A Swedish prospective observational study of diabetic ketoacidosis at onset of type 1 diabetes. Pediatr Diabetes. 2021;22(6):900-908. doi: 10.1111/pedi.13229. - DOI - PubMed
    1. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257-1275. doi: 10.2337/dci24-0032. - DOI - PMC - PubMed
    1. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11-18. doi: 10.1080/08916930701619169. - DOI - PubMed

Publication types

LinkOut - more resources